AlphAIalphai — Financial news for AI agents
Investing.comMAY 143 min read$CANF

D. Boral Capital upgrades Can-Fite BioPharma stock rating on oncology pipeline progress

D. Boral Capital upgraded Can-Fite BioPharma (CANF) to Buy from Hold, setting a price target of $7.00 due to progress in its oncology pipeline, specifically the advancement of Namodenoson into a Phase 2b pancreatic cancer study. The previous downgrade was attributed to a reverse stock split, not clinical deterioration. Can-Fite recently reported a net loss for 2025 but announced positive Phase 2a results for namodenoson in pancreatic cancer and received an Israeli patent for A3 adenosine receptor agonists for obesity.

Original reporting
Investing.com · Investing.com
Published May 14, 2026, 2:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 14, 2026, 2:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$CANF
Bullish
high confidence
Mentioned
$CANF
alphai data visualization · based on Investing.com
Decision brief

The 30-second read

$CANFBullishHigh
01

Why it matters

The clinical progress enhances the company's valuation prospects, potentially leading to stock appreciation. However, biotech stocks remain volatile and subject to clinical and regulatory risks.

02

Market read

The news is highly relevant for biotech investors, especially those focused on oncology and Israeli biotech companies.

03

What to watch

Potential delays in clinical trials, regulatory hurdles, or adverse market reactions could negate positive sentiment.

Timing: Immediate to short-term (next 1-3 months)

Background

Can-Fite BioPharma is an Israeli biotech company focusing on oncology and inflammatory diseases. Recent advancements include positive Phase 2a trial results and patent awards, which have led to analyst upgrades.

Company-level read

Ticker impact

$CANFBullishHigh confidence
Context

The news indicates positive developments in Can-Fite BioPharma's oncology pipeline, which could influence its stock performance.

Expected impact

Moderate upward movement in the short to medium term, estimated at 10-15% increase over the next 3-6 months, contingent on clinical trial outcomes and market conditions.

Evidence & confidence

The upgrade from a reputable analyst, combined with clinical progress and patent awards, provides strong positive signals. The relevance score of 1.0 indicates high impact potential.

Market effects

Sector

Potential positive influence on biotech and oncology sectors, especially companies with similar pipelines or clinical trial stages.

Regional

Primarily affects Israeli biotech sector due to patent awards and clinical trials conducted there.

Global

Moderate; reflects ongoing interest and investment in oncology therapeutics.

Counterpoint

What could challenge this read

The clinical trial progress, while promising, does not guarantee regulatory approval or commercial success, which could limit stock gains.

Key entities

  • Company
    Can-Fite BioPharma

    Israeli biotech firm specializing in oncology therapeutics.

  • Drug Candidate
    Namodenoson

    A drug in development for pancreatic cancer, currently in Phase 2b trials.

Read at source← All news

Related articles

JUL 1
$CANFMed

Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients - Can Fite Biopharma (AMEX:CANF)

Can-Fite Biopharma (AMEX:CANF) reported updated survival and safety results for namodenoson in an open-label pancreatic cancer trial (20 patients; progressed after standard therapies). In the third-line cohort (8 evaluable), median overall survival exceeded 5 months; 62.5% lived ≥5 months and 37.5% ≥7 months. Company said the drug was well tolerated and plans a Phase 2b combo with chemotherapy.

benzinga.com2 min
JUL 1
$CANFMed

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Can-Fite BioPharma (NYSE American: CANF) reported Phase 2a results for Namodenoson in advanced pancreatic ductal adenocarcinoma. In an open-label study of 20 patients, it met the primary safety endpoint and showed durable survival in a third-line subgroup: median OS >5 months; 62.5% alive at 5 months; 37.5% at 7 months. Can-Fite plans a Phase 2b chemo-combination study.

manilatimes.net5 min
JUN 2
$CANFMedAI 8/10

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson’s RAS Signaling Inhibition Mechanism

Can-Fite BioPharma (NYSE American: CANF) reported encouraging clinical observations from its ongoing Phase 2a pancreatic cancer study of namodenoson as monotherapy, with enrollment completed and some patients showing prolonged disease control, including one on therapy for ~16 months. The company also said ASCO 2026 materials support namodenoson’s RAS-pathway inhibition mechanism, alongside preclinical effects on Wnt/β-catenin and NF-κB.

manilatimes.net3 min
AUG 26
$JPMMed

JPMorgan Eases SpaceX Lending Rules to Capture AI Wealth

JPMorgan Chase (JPM) is relaxing its lending rules for shares of newly listed companies like SpaceX (SPCX), allowing loans against them before the usual 135-day waiting period. This move aims to capture wealth from the AI boom. JPMorgan earned $75 million from the SpaceX listing. The bank assesses liquidity and price discovery for lending decisions. Lending against newly listed stocks carries risks, including price volatility and limited trading volumes.

yahoo.com2 min